Tert-butyl 8-[tert-butyl(dimethyl)silyl]oxy-4-[4-(diethylcarbamoyl)phenyl]spiro[chromene-2,4'-piperidine]-1'-carboxylate | 1013334-06-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 新黄酮类化合物
• 英文名称: Tert-butyl 8-[tert-butyl(dimethyl)silyl]oxy-4-[4-(diethylcarbamoyl)phenyl]spiro[chromene-2,4'-piperidine]-1'-carboxylate
• CAS: 1013334-06-9
• 化学式: C₃₅H₅₀N₂O₅Si
• 分子量: 606.878
• InChiKey: MUQNEBTUQMFCAW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.15
• 重原子数：
  43
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  68.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Tert-butyl 8-[tert-butyl(dimethyl)silyl]oxy-4-[4-(diethylcarbamoyl)phenyl]spiro[chromene-2,4'-piperidine]-1'-carboxylate 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 生成 Tert-butyl 4-[4-(diethylcarbamoyl)phenyl]-8-hydroxyspiro[chromene-2,4'-piperidine]-1'-carboxylate
  参考文献：
  名称：

  Potent, Orally Bioavailable Delta Opioid Receptor Agonists for the Treatment of Pain: Discovery of N,N-Diethyl-4-(5-hydroxyspiro[chromene-2,4′-piperidine]-4-yl)benzamide (ADL5859)

  摘要：

  Selective 6 opioid receptor agonists are promising potential therapeutic agents for the treatment of various types of pain conditions. A spirocyclic derivative was identified as a promising hit through screening. Subsequent lead optimization identified compound 20 (ADL5859) as a potent, selective, and orally bioavailable 6 agonist. Compound 20 was selected as a clinical candidate for the treatment of pain.

  DOI：

  10.1021/jm8008986
• 作为产物：
  描述：

  Tert-butyl 8-[tert-butyl(dimethyl)silyl]oxy-4-(trifluoromethylsulfonyloxy)spiro[chromene-2,4'-piperidine]-1'-carboxylate 、 4-(N,N-二乙氨甲酰基)苯硼酸 在 四(三苯基膦)钯 、 sodium carbonate 、 lithium chloride 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 4.0h， 生成 Tert-butyl 8-[tert-butyl(dimethyl)silyl]oxy-4-[4-(diethylcarbamoyl)phenyl]spiro[chromene-2,4'-piperidine]-1'-carboxylate
  参考文献：
  名称：

  Potent, Orally Bioavailable Delta Opioid Receptor Agonists for the Treatment of Pain: Discovery of N,N-Diethyl-4-(5-hydroxyspiro[chromene-2,4′-piperidine]-4-yl)benzamide (ADL5859)

  摘要：

  Selective 6 opioid receptor agonists are promising potential therapeutic agents for the treatment of various types of pain conditions. A spirocyclic derivative was identified as a promising hit through screening. Subsequent lead optimization identified compound 20 (ADL5859) as a potent, selective, and orally bioavailable 6 agonist. Compound 20 was selected as a clinical candidate for the treatment of pain.

  DOI：

  10.1021/jm8008986